See more : Stelux Holdings International Limited (0084.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Psychemedics Corporation (PMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Psychemedics Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- New Concept Energy, Inc. (GBR) Income Statement Analysis – Financial Results
- Staffline Group plc (STAF.L) Income Statement Analysis – Financial Results
- Sompo Holdings, Inc. (SMPNY) Income Statement Analysis – Financial Results
- Vedanta Limited (VEDL.BO) Income Statement Analysis – Financial Results
- Michlol Finance Ltd (MCLL.TA) Income Statement Analysis – Financial Results
Psychemedics Corporation (PMD)
About Psychemedics Corporation
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.10M | 25.24M | 24.91M | 21.36M | 37.68M | 42.67M | 39.70M | 38.98M | 26.98M | 29.20M | 26.87M | 25.22M | 24.09M | 20.11M | 16.95M | 22.95M | 24.57M | 23.43M | 21.39M | 18.94M | 16.00M | 16.07M | 15.73M | 19.22M | 19.60M | 17.70M | 15.40M | 12.20M | 10.10M | 8.70M | 6.60M | 4.00M | 2.50M | 1.70M | 300.00K | 100.00K |
| Cost of Revenue | 13.69M | 15.95M | 14.65M | 16.47M | 21.23M | 22.06M | 19.88M | 17.53M | 14.26M | 14.07M | 11.48M | 10.97M | 9.62M | 8.07M | 7.35M | 9.60M | 9.89M | 9.37M | 8.81M | 8.49M | 7.63M | 7.02M | 7.82M | 8.90M | 7.20M | 6.50M | 5.40M | 4.50M | 4.20M | 3.30M | 2.40M | 1.60M | 1.40M | 1.00M | 1.30M | 300.00K |
| Gross Profit | 8.41M | 9.29M | 10.26M | 4.89M | 16.44M | 20.62M | 19.82M | 21.45M | 12.72M | 15.14M | 15.39M | 14.25M | 14.47M | 12.04M | 9.61M | 13.35M | 14.68M | 14.06M | 12.58M | 10.45M | 8.37M | 9.05M | 7.92M | 10.32M | 12.40M | 11.20M | 10.00M | 7.70M | 5.90M | 5.40M | 4.20M | 2.40M | 1.10M | 700.00K | -1.00M | -200.00K |
| Gross Profit Ratio | 38.07% | 36.81% | 41.21% | 22.87% | 43.64% | 48.32% | 49.93% | 55.03% | 47.14% | 51.83% | 57.29% | 56.50% | 60.08% | 59.88% | 56.68% | 58.17% | 59.74% | 60.00% | 58.80% | 55.17% | 52.33% | 56.32% | 50.32% | 53.72% | 63.27% | 63.28% | 64.94% | 63.11% | 58.42% | 62.07% | 63.64% | 60.00% | 44.00% | 41.18% | -333.33% | -200.00% |
| Research & Development | 1.14M | 1.33M | 1.13M | 1.28M | 1.57M | 1.55M | 1.36M | 1.42M | 1.63M | 1.35M | 825.10K | 825.52K | 607.41K | 481.43K | 467.44K | 474.62K | 489.01K | 444.53K | 335.77K | 329.42K | 305.68K | 358.10K | 608.19K | 475.70K | 500.00K | 500.00K | 400.00K | 400.00K | 400.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.19M | 5.86M | 6.13M | 6.10M | 7.22M | 6.43M | 5.64M | 4.97M | 4.56M | 4.47M | 4.16M | 3.95M | 3.95M | 4.20M | 3.60M | 4.52M | 7.05M | 6.05M | 5.91M | 5.79M | 6.13M | 6.76M | 6.98M | 7.42M | 7.10M | 6.40M | 5.90M | 4.40M | 3.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.00M | 3.19M | 2.80M | 3.58M | 4.66M | 5.03M | 4.67M | 4.96M | 5.05M | 4.63M | 4.70M | 4.54M | 4.12M | 2.95M | 2.96M | 3.65M | 12.50K | 0.00 | 0.00 | 0.00 | 2.82B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.19M | 9.05M | 8.93M | 9.67M | 11.88M | 11.46M | 10.31M | 9.93M | 9.61M | 9.10M | 8.86M | 8.49M | 8.06M | 7.15M | 6.56M | 8.17M | 7.05M | 6.05M | 5.91M | 5.79M | 6.13M | 6.76M | 6.98M | 7.42M | 7.10M | 6.40M | 5.90M | 4.40M | 3.70M | 2.80M | 2.90M | 2.70M | 2.30M | 2.60M | 0.00 | 1.70M |
| Other Expenses | 0.00 | 43.00K | -1.03M | -140.00K | 58.00K | 43.00K | 20.00K | -134.00K | -124.59K | -56.58K | 92.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.30M | 1.00M | 700.00K | 500.00K | 600.00K | 400.00K | 300.00K | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K |
| Operating Expenses | 11.33M | 10.37M | 10.06M | 10.95M | 13.45M | 13.01M | 11.67M | 11.34M | 11.25M | 10.45M | 9.69M | 9.32M | 8.67M | 7.63M | 7.03M | 8.64M | 7.54M | 6.49M | 6.25M | 6.12M | 6.43M | 7.11M | 7.59M | 7.89M | 8.90M | 7.90M | 7.00M | 5.30M | 4.70M | 3.60M | 3.20M | 2.90M | 2.50M | 2.80M | 100.00K | 1.80M |
| Cost & Expenses | 25.02M | 26.32M | 24.70M | 27.43M | 34.68M | 35.06M | 31.54M | 28.87M | 25.50M | 24.52M | 21.16M | 20.29M | 18.29M | 15.69M | 14.37M | 18.24M | 17.43M | 15.86M | 15.06M | 14.61M | 14.06M | 14.13M | 15.41M | 16.79M | 16.10M | 14.40M | 12.40M | 9.80M | 8.90M | 6.90M | 5.60M | 4.50M | 3.90M | 3.80M | 1.40M | 2.10M |
| Interest Income | 0.00 | 0.00 | 49.00K | 75.00K | 134.00K | 149.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.89K | 5.35K | 23.09K | 45.32K | 308.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 49.00K | 75.00K | 59.00K | 106.00K | 0.00 | 134.00K | 124.59K | 56.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.67M | 3.32M | 3.69M | 3.63M | 2.91M | 3.06M | 2.81M | 2.29M | 1.73M | 1.05M | 872.17K | 586.97K | 370.02K | 284.91K | 336.80K | 331.39K | 347.13K | 287.44K | 408.97K | 533.59K | 871.99K | 1.14M | 1.27M | 1.28M | 1.30M | 1.00M | 700.00K | 500.00K | 600.00K | 400.00K | 300.00K | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K |
| EBITDA | -251.00K | 2.23M | 3.90M | -2.44M | 5.91M | 7.61M | 10.96M | 12.40M | 2.75M | 5.49M | 6.58M | 5.52M | 6.17M | 4.70M | 2.92M | 5.04M | 7.49M | 7.85M | 6.74M | 4.86M | 2.81M | 3.08M | 1.59M | 3.71M | 4.80M | 4.30M | 3.70M | 2.90M | 1.80M | 2.20M | 1.30M | -300.00K | -1.20M | -1.90M | -1.00M | -400.00K |
| EBITDA Ratio | -1.14% | -4.29% | 0.84% | -28.40% | 7.96% | 17.83% | 20.55% | 25.94% | 5.45% | 16.06% | 21.24% | 19.57% | 25.61% | 23.37% | 15.24% | 21.95% | 30.47% | 33.51% | 31.48% | 25.62% | 17.57% | 18.31% | 10.11% | 16.88% | 24.49% | 20.90% | 20.78% | 20.49% | 13.86% | 22.99% | 19.70% | -10.00% | -48.00% | -111.76% | -333.33% | -2,000.00% |
| Operating Income | -2.92M | -1.08M | -3.48M | -6.07M | 84.00K | 7.65M | 8.16M | 10.11M | 1.47M | 4.69M | 5.71M | 4.94M | 5.80M | 4.41M | 2.58M | 4.71M | 7.14M | 7.56M | 6.33M | 4.33M | 1.94M | 1.94M | 323.19K | 2.43M | 3.50M | 3.30M | 3.00M | 2.40M | 1.20M | 1.80M | 1.00M | -500.00K | -1.40M | -2.10M | -1.10M | -2.00M |
| Operating Income Ratio | -13.22% | -4.29% | -13.97% | -28.40% | 0.22% | 17.93% | 20.55% | 25.94% | 5.45% | 16.06% | 21.24% | 19.57% | 24.08% | 21.95% | 15.24% | 20.51% | 29.06% | 32.29% | 29.58% | 22.87% | 12.12% | 12.05% | 2.05% | 12.64% | 17.86% | 18.64% | 19.48% | 19.67% | 11.88% | 20.69% | 15.15% | -12.50% | -56.00% | -123.53% | -366.67% | -2,000.00% |
| Total Other Income/Expenses | -517.00K | 43.00K | -1.03M | -140.00K | 58.00K | 43.00K | 20.00K | -134.00K | -124.00K | -57.00K | 92.27K | 1.89K | 5.35K | 23.09K | 45.32K | 308.03K | 416.65K | 294.04K | 122.20K | 47.73K | 41.13K | 178.70K | 125.33K | 461.64K | 400.00K | 600.00K | 600.00K | 400.00K | 500.00K | 100.00K | 0.00 | 100.00K | 0.00 | 0.00 | 0.00 | 500.00K |
| Income Before Tax | -3.44M | -1.04M | -821.00K | -6.21M | 3.06M | 7.65M | 8.18M | 9.98M | 1.35M | 4.63M | 5.80M | 4.94M | 5.81M | 4.44M | 2.63M | 5.01M | 7.56M | 7.86M | 6.45M | 4.38M | 1.98M | 2.11M | 448.53K | 2.89M | 3.90M | 3.90M | 3.60M | 2.80M | 1.70M | 1.90M | 0.00 | -400.00K | 0.00 | 0.00 | 0.00 | -1.90M |
| Income Before Tax Ratio | -15.56% | -4.12% | -3.30% | -29.05% | 8.11% | 17.93% | 20.60% | 25.59% | 4.99% | 15.86% | 21.58% | 19.58% | 24.10% | 22.07% | 15.51% | 21.85% | 30.75% | 33.54% | 30.15% | 23.12% | 12.37% | 13.16% | 2.85% | 15.04% | 19.90% | 22.03% | 23.38% | 22.95% | 16.83% | 21.84% | 0.00% | -10.00% | 0.00% | 0.00% | 0.00% | -1,900.00% |
| Income Tax Expense | 716.00K | 44.00K | -156.00K | -2.35M | 1.51M | 3.07M | 2.06M | 3.30M | -164.39K | 1.43M | 1.99M | 1.96M | 2.32M | 1.82M | 1.10M | 2.05M | 3.07M | 2.96M | 2.40M | 1.62M | 760.80K | 859.00K | 216.00K | 1.19M | 1.60M | 1.50M | 1.10M | 300.00K | 100.00K | 100.00K | 0.00 | -100.00K | 100.00K | 0.00 | -100.00K | -300.00K |
| Net Income | -4.15M | -1.08M | -665.00K | -3.86M | 1.54M | 4.58M | 6.12M | 6.68M | 1.51M | 3.21M | 3.81M | 2.98M | 3.49M | 2.61M | 1.53M | 2.97M | 4.48M | 4.90M | 4.05M | 2.76M | 1.22M | 1.26M | 232.53K | 1.70M | 2.30M | 2.40M | 2.50M | 2.50M | 1.60M | 1.80M | 1.00M | -500.00K | -1.50M | -2.10M | -1.00M | -1.80M |
| Net Income Ratio | -18.80% | -4.29% | -2.67% | -18.07% | 4.09% | 10.74% | 15.42% | 17.13% | 5.60% | 10.98% | 14.16% | 11.81% | 14.48% | 13.00% | 9.01% | 12.94% | 18.25% | 20.93% | 18.93% | 14.59% | 7.62% | 7.81% | 1.48% | 8.84% | 11.73% | 13.56% | 16.23% | 20.49% | 15.84% | 20.69% | 15.15% | -12.50% | -60.00% | -123.53% | -333.33% | -1,800.00% |
| EPS | -0.72 | -0.19 | -0.12 | -0.70 | 0.28 | 0.83 | 1.11 | 1.23 | 0.28 | 0.60 | 0.72 | 0.57 | 0.67 | 0.50 | 0.29 | 0.57 | 0.86 | 0.95 | 0.79 | 0.54 | 0.23 | 0.24 | 0.04 | 0.32 | 0.44 | 0.44 | 0.44 | 0.44 | 0.27 | 1.55 | 0.93 | -0.13 | -0.39 | -0.71 | -0.39 | -1.10 |
| EPS Diluted | -0.72 | -0.19 | -0.12 | -0.70 | 0.28 | 0.83 | 1.10 | 1.22 | 0.28 | 0.60 | 0.72 | 0.57 | 0.67 | 0.50 | 0.29 | 0.57 | 0.85 | 0.94 | 0.78 | 0.54 | 0.23 | 0.24 | 0.04 | 0.32 | 0.44 | 0.44 | 0.44 | 0.44 | 0.27 | 1.40 | 0.78 | -0.13 | -0.39 | -0.71 | -0.39 | -1.10 |
| Weighted Avg Shares Out | 5.74M | 5.63M | 5.55M | 5.52M | 5.51M | 5.51M | 5.49M | 5.45M | 5.41M | 5.36M | 5.30M | 5.26M | 5.23M | 5.21M | 5.19M | 5.22M | 5.21M | 5.17M | 5.16M | 5.13M | 5.19M | 5.26M | 5.29M | 5.31M | 5.46M | 5.55M | 5.49M | 5.54M | 5.85M | 5.02M | 3.87M | 3.87M | 3.82M | 2.94M | 2.60M | 1.63M |
| Weighted Avg Shares Out (Dil) | 5.74M | 5.63M | 5.55M | 5.52M | 5.53M | 5.52M | 5.56M | 5.48M | 5.41M | 5.38M | 5.32M | 5.27M | 5.24M | 5.23M | 5.20M | 5.25M | 5.30M | 5.24M | 5.17M | 5.13M | 5.20M | 5.28M | 5.34M | 5.37M | 5.51M | 5.65M | 5.64M | 5.54M | 5.85M | 5.02M | 3.87M | 3.87M | 3.82M | 2.94M | 2.60M | 1.63M |
Psychemedics Corporation Announces Reverse and Forward Stock Split
DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq: PMD) (the “Company”), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders...
Psychemedics Corporation Reports Third Quarter 2024 Financial Results
DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024.
Psychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair Testing
DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever Education Insights Report.
Psychemedics Corporation Reports Second Quarter 2024 Financial Results
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the second quarter ending June 30, 2024.
Psychemedics Corporation's Board of Directors Approves Plan to Terminate Registration of Its Common Stock
DALLAS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) (“Psychemedics” or the “Company”) today announced that a Transaction Committee (the “Transaction Committee”) of the Board of Directors of the Company (the “Board”) comprised of independent directors has recommended, and...
Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace,...
Psychemedics Corporation Reports First Quarter 2024 Financial Results
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024.
Psychemedics Corporation Reports 2023 Financial Results
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world's leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023.
Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider
Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024...
Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas
ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to...
Source: https://incomestatements.info
Category: Stock Reports